AXSM · Healthcare
Axsome Therapeutics Inc.
24/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
32
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$11.2B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGM
About AXSOME THERAPEUTICS INC.
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the…
Who's behind the signal
Every informed buyer we can see on AXSM, across all three feeds.
Hedge funds · 6
Point72 (Steve Cohen)
Increased +2260%
D.E. Shaw & Co
Increased +10%
Bridgewater Associates (Dalio)
Increased +20%
Citadel Advisors
Increased +104%
AQR Capital Management
Unchanged
Millennium Management (Englander)
Decreased −39%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 1 on record
Disclosures from 2022-06-16 to 2022-06-16
The newest disclosure we hold for this stock is 2022-06-16.
That is the end of our data, not necessarily the end of the trading — our
bulk STOCK Act archive stops there and newer filings arrive through a
separate live feed. Treat the absence of recent rows as “not covered”,
not as “no trades”.
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2022-06-16 | Chris Jacobs · R-NY | House | Bought | $15,001 - $50,000 |
Not a model pick — but on our radar.
AXSOME THERAPEUTICS INC. isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
0
New positions
4
Increasing
1
Decreasing
1
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.1×
% of portfolio
0.1%
Position change
+2260%
0.1% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
+10%
0.1% of D.E. Shaw & Co's portfolio
Trust weight: 1.3×
% of portfolio
0.0%
Position change
+20%
0.0% of Bridgewater Associates's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+104%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
—
0.0% of AQR Capital Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−39%
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to AXSOME THERAPEUTICS INC.
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell AXSOME THERAPEUTICS INC. or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订